BioSpace News Archive

Regeneron Pharmaceuticals, Inc. and Sanofi announced the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Dupixent® for the treatment of patients 12 years and older with eosinophilic esophagitis.

Dynavax will provide CpG 1018 to produce up to 190 million doses over a five year period to support Valneva’s contract with the U.K. government

SanBio Co., Ltd. hereby announces that it has obtained new analytical results from the Phase 2b clinical trial of SB623 for the treatment of chronic motor deficit resulting from ischemic stroke the SanBio Group conducted in the US.

The ability to speak with a pharmacist has become increasingly difficult in recent years, as most licensed pharmacists have little or no time to interact with patients and doctors.

Presentation to highlight the scientific characteristics of the novel first-in-class anti Globo H antibody-drug conjugate (ADC), OBI-999

Vertex Pharmaceuticals Incorporated announced the European Medicines Agency has validated a Type II Variation Marketing Authorization Application for the expanded indication of KAFTRIO®* in combination with ivacaftor to treat CF in patients ages 12 years and older with at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

Vizgen, the company illuminating biology with the next generation of spatially resolved, single-cell genomics tools, announced the appointment of Terry Lo as President and Chief Executive Officer, effective immediately.

Innovent Biologics, Inc. and Eli Lilly and Company jointly announce that results of six clinical studies of TYVYT® will be presented during the upcoming European Society of Medical Oncology Virtual Congress 2020 from September 19th to 21st.

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of oncolytic immunotherapeutics for cancer based on Seneca Valley Virus, announced the receipt of positive guidance from the FDA on the reactivation of the SVV-001 IND and Phase I/II protocol.

Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities